RedHill Biopharma's (RDHL) Movantik Added To Medicare Part D Formulary
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
RedHill’s Movantik Added To Medicare Formulary
December 1, 2021 7:04 AM ESTRedHill Biopharma's Movantik Added as Preferred and
Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans
Movantik approved for inclusion as preferred and unrestricted brand on a major National
Medicare Part D formulary serving more than 10 million Americans as of January 1, 2022
-
Movantik's total commercial coverage extends to 152 million American patients' lives and
will grow to 46 million Medicare lives and will increase to over 94% coverage of Medicare Part D... More
